{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:52:29Z","timestamp":1768917149622,"version":"3.49.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0681-6","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T09:53:00Z","timestamp":1500285180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["An update on the use of biologic therapies in the management of uveitis in Beh\u00e7et\u2019s disease: a comprehensive review"],"prefix":"10.1186","volume":"12","author":[{"given":"Thomas W.","family":"McNally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika M.","family":"Damato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip I.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair K.","family":"Denniston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"681_CR1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-9-16","volume":"9","author":"RJ Barry","year":"2014","unstructured":"Barry RJ, Markandey B, Malhotra R, Knott H, Joji N, Mubin M, et al. Evidence-based practice in Beh\u00e7et\u2019s disease: identifying areas of unmet need for 2014. Orphanet J Rare Dis. 2014;9:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"681_CR2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/BOR.0b013e3282f154d1","volume":"20","author":"I Krause","year":"2008","unstructured":"Krause I, Weinberger A. Beh\u00e7et's disease. Curr Opin Rheumatol. 2008;20(1):82\u20137.","journal-title":"Curr Opin Rheumatol"},{"issue":"17","key":"681_CR3","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. NEJM. 1999;341(17):1284\u201391.","journal-title":"NEJM"},{"key":"681_CR4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00002281-200401000-00008","volume":"16","author":"S Yurdakul","year":"2004","unstructured":"Yurdakul S, Hamuryudan V, Yazici H. Beh\u00e7et syndrome. Curr Opin Rheumatol. 2004;16:38.","journal-title":"Curr Opin Rheumatol"},{"key":"681_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/bjo.40.6.355","volume":"40","author":"A Feigenbaum","year":"1956","unstructured":"Feigenbaum A. Description of Beh\u00e7et's syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol. 1956;40:355.","journal-title":"Br J Ophthalmol"},{"key":"681_CR6","first-page":"1078","volume":"335","author":"B Wechsler","year":"1990","unstructured":"Wechsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N, Kansu E, et al. Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet. 1990;335:1078\u201380.","journal-title":"Lancet"},{"key":"681_CR7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.60.11.996","volume":"60","author":"H Direskeneli","year":"2001","unstructured":"Direskeneli H. Beh\u00e7et's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60:996.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"681_CR8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1474-4422(09)70015-8","volume":"8","author":"A Al-Araji","year":"2009","unstructured":"Al-Araji A, Kidd DP. Neuro-Beh\u00e7et's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192\u2013204.","journal-title":"Lancet Neurol"},{"issue":"6","key":"681_CR9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11926-010-0132-z","volume":"12","author":"Y Yazici","year":"2010","unstructured":"Yazici Y, Yurdakul S, Yazici H. Beh\u00e7et\u2019s syndrome. Curr Rheumatol Rep. 2010;12(6):429\u201335.","journal-title":"Curr Rheumatol Rep"},{"key":"681_CR10","first-page":"1689","volume":"29","author":"CC Mok","year":"2002","unstructured":"Mok CC, Cheung TC, Ho CT, Lee KW, Lau CS, Wong RW. Beh\u00e7et's disease in southern Chinese patients. J Rheumatol. 2002;29:1689.","journal-title":"J Rheumatol"},{"key":"681_CR11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.22500","volume":"57","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiati B, Macchioni P, et al. Epidemiology and clinical course of Beh\u00e7et's disease in the Reggio Emilia area of northern Italy: a seventeen-year population-based study. Arthritis Rheum. 2007;57:171.","journal-title":"Arthritis Rheum"},{"key":"681_CR12","first-page":"28","volume":"31","author":"I Olivieri","year":"2013","unstructured":"Olivieri I, Leccese P, Padula A, Nigro A, Palazzi C, Gilio M, et al. High prevalence of Beh\u00e7et's disease in southern Italy. Clin Exp Rheumatol. 2013;31:28.","journal-title":"Clin Exp Rheumatol"},{"key":"681_CR13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-9-42","volume":"9","author":"L Savey","year":"2014","unstructured":"Savey L, Resche-Rigon M, Wechsler B, Comarmond C, Piette JC, Cacoub P, et al. Ethnicity and association with disease manifestations and mortality in Beh\u00e7et's disease. Orphanet J Rare Dis. 2014;9:42.","journal-title":"Orphanet J Rare Dis"},{"key":"681_CR14","first-page":"391","volume":"1","author":"T Akpolat","year":"1992","unstructured":"Akpolat T, Ko\u00e7 Y, Yeniay I, Akpek G, G\u00fcll\u00fcI KE, et al. Familial Beh\u00e7et's disease. Eur J Med. 1992;1:391.","journal-title":"Eur J Med"},{"key":"681_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-3476(99)70333-1","volume":"135","author":"I Kon\u00e9-Paut","year":"1999","unstructured":"Kon\u00e9-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, et al. Familial aggregation in Beh\u00e7et's disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135:89.","journal-title":"J Pediatr"},{"key":"681_CR16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2169\/internalmedicine.51.6858","volume":"51","author":"B G\u00fclbay","year":"2012","unstructured":"G\u00fclbay B, Acican T, Er\u00e7en Diken \u00d6, Pinar \u00d6nen Z. Familial Beh\u00e7et's disease of adult age: a report of 4 cases from a Beh\u00e7et family. Intern Med. 2012;51:1609.","journal-title":"Intern Med"},{"issue":"Suppl. 24","key":"681_CR17","first-page":"S6","volume":"19","author":"A G\u00fcl","year":"2001","unstructured":"G\u00fcl A. Beh\u00e7et's disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001;19(Suppl. 24):S6\u2013S12.","journal-title":"Clin Exp Rheumatol"},{"key":"681_CR18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.24642","volume":"61","author":"M Menthon de","year":"2009","unstructured":"de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51\/B5 and the risk of Beh\u00e7et's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287.","journal-title":"Arthritis Rheum"},{"key":"681_CR19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C. Current concepts in the etiology and treatment of Beh\u00e7et disease. Surv Ophthalmol. 2005;50:297.","journal-title":"Surv Ophthalmol"},{"key":"681_CR20","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1529-0131(200107)44:7<1707::AID-ART295>3.0.CO;2-P","volume":"44","author":"CH Suh","year":"2001","unstructured":"Suh CH, Park YB, Song J, Lee CH, Lee SK. Oligoclonal B lymphocyte expansion in the synovium of a patient with Beh\u00e7et's disease. Arthritis Rheum. 2001;44:1707.","journal-title":"Arthritis Rheum"},{"key":"681_CR21","first-page":"826","volume":"26","author":"E Ek\u015fioglu-Demiralp","year":"1999","unstructured":"Ek\u015fioglu-Demiralp E, Kibaroglu A, Direskeneli H, Yavuz S, Karsli F, Yurdakul S, et al. Phenotypic characteristics of B cells in Beh\u00e7et's disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826.","journal-title":"J Rheumatol"},{"key":"681_CR22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-3083.1996.d01-53.x","volume":"43","author":"H Direskeneli","year":"1996","unstructured":"Direskeneli H, Hasan A, Shinnick T, Mizushima R, van der Zee R, Fortune F, et al. Recognition of B-cell epitopes of the 65 kDa HSP in Beh\u00e7et's disease. Scand J Immunol. 1996;43:464.","journal-title":"Scand J Immunol"},{"key":"681_CR23","first-page":"S32","volume":"27","author":"G Mumcu","year":"2009","unstructured":"Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H. Association of salivary S. Mutans colonisation and mannose-binding lectin deficiency with gender in Beh\u00e7et's disease. Clin Exp Rheumatol. 2009;27:S32.","journal-title":"Clin Exp Rheumatol"},{"key":"681_CR24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1742-1241.2005.00477.x","volume":"59","author":"H Oflaz","year":"2005","unstructured":"Oflaz H, Mercanoglu F, Karaman O, Kamali S, Erer B, Genchellac H, et al. Impaired endothelium-dependent flow-mediated dilation in Beh\u00e7et's disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract. 2005;59:777.","journal-title":"Int J Clin Pract"},{"key":"681_CR25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1006\/clim.1999.4687","volume":"91","author":"G Triolo","year":"1999","unstructured":"Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selectin expression by sera from patients with active Beh\u00e7et's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol. 1999;91:330.","journal-title":"Clin Immunol"},{"key":"681_CR26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0140-6736(86)90552-0","volume":"2","author":"E Kansu","year":"1986","unstructured":"Kansu E, Sahin G, Sahin F, Sivri B, Sayek I, Batman F. Impaired prostacyclin synthesis by vessel walls in Beh\u00e7et's disease. Lancet. 1986;2:1154.","journal-title":"Lancet"},{"issue":"4","key":"681_CR27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.autrev.2014.11.009","volume":"14","author":"C Consolandi","year":"2015","unstructured":"Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, Biagi E, et al. Beh\u00e7et\u2019s syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015 April;14(4):269\u201376.","journal-title":"Autoimmun Rev"},{"key":"681_CR28","doi-asserted-by":"crossref","unstructured":"Denniston AKO, Murray PI. Oxford Handbook of Ophthalmology. 3rd ed. Oxford: Oxford University Press; 2009.","DOI":"10.1093\/med\/9780199552641.001.0001"},{"key":"681_CR29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/08830189709116845","volume":"14","author":"RB Nussenblatt","year":"1997","unstructured":"Nussenblatt RB. Uveitis in Beh\u00e7et's disease. Int Rev Immunol. 1997;14:67.","journal-title":"Int Rev Immunol"},{"key":"681_CR30","first-page":"8","volume":"5","author":"E Seyahi","year":"2007","unstructured":"Seyahi E, Melikoglu M, Yazici H. Clinical features and diagnosis of Beh\u00e7et's syndrome. Int J Adv Rheumatol. 2007;5:8.","journal-title":"Int J Adv Rheumatol"},{"issue":"Suppl. 94","key":"681_CR31","first-page":"S3","volume":"33","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. Beh\u00e7et\u2019s syndrome: a critical digest of the 2014-2015 literature. Clin Exp Rheumatol. 2015;33(Suppl. 94):S3\u2013S14.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"681_CR32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Opthalmol. 1996;80(4):332\u20136.","journal-title":"Br J Opthalmol"},{"key":"681_CR33","first-page":"67","volume":"8","author":"S Pasadhika","year":"2014","unstructured":"Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67\u201381.","journal-title":"Biologics"},{"key":"681_CR34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"681_CR35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/bjo.82.6.704","volume":"82","author":"RM Stanbury","year":"1998","unstructured":"Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol. 1998;82(6):704\u20138.","journal-title":"Br J Ophthalmol"},{"key":"681_CR36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2007.0015","volume":"23","author":"S Tuncer","year":"2007","unstructured":"Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide [IVTA] injection for the treatment of panuveitis attacks in patients with Beh\u00e7et disease. J Ocul Pharmacol Ther. 2007;23:395.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"681_CR37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","volume":"149","author":"E Daniel","year":"2010","unstructured":"Daniel E, Thorne JE, Newcomb CW, Pujari SS, Ka\u00e7maz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423\u201332.","journal-title":"Am J Ophthalmol"},{"key":"681_CR38","doi-asserted-by":"crossref","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of Infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet, 2001. 358(9278):295\u20136.","DOI":"10.1016\/S0140-6736(01)05497-6"},{"key":"681_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et\u2019s disease. Auto- immun Rev. 2015;14:1\u20139.","journal-title":"Auto- immun Rev"},{"key":"681_CR40","first-page":"1891","volume":"8","author":"RJ Barry","year":"2014","unstructured":"Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Opth. 2014;8:1891\u2013911.","journal-title":"Clin Opth"},{"key":"681_CR41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by Canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series. Dermatology. 2014;228:21\u20134.","journal-title":"Dermatology"},{"issue":"5","key":"681_CR42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N. The use of interferon alpha in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320\u201335.","journal-title":"Semin Arthritis Rheum"},{"key":"681_CR43","doi-asserted-by":"crossref","first-page":"286857","DOI":"10.1155\/2013\/286857","volume":"2013","author":"D S\u00e1nchez-Cano","year":"2013","unstructured":"S\u00e1nchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, R\u00edos-Fern\u00e1ndez R, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Beh\u00e7et\u2019s disease, Sarcoidosis, and noninfectious Uveitis. Mediat Inflamm. 2013;2013:286857.","journal-title":"Mediat Inflamm"},{"key":"681_CR44","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of Etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98.","journal-title":"J Rheumatol"},{"key":"681_CR45","first-page":"S54","volume":"32 Suppl 84","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, de la Hera D, Beltr\u00e1n-Catal\u00e1n E, Blanco R, Hernandez M, Mart\u00ednez-Costa L, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheum. 2014;32 Suppl 84:S54\u20137.","journal-title":"Clin Exp Rheum"},{"key":"681_CR46","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","volume":"44","author":"O Addimanda","year":"2015","unstructured":"Addimanda O, Pipitone N, Pazzola G, Salvarani C. Tocilizumab for severe re- fractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et. Semin Arthritis Rheum. 2015;44:472\u20135.","journal-title":"Semin Arthritis Rheum"},{"key":"681_CR47","first-page":"S75","volume":"32 Suppl 84","author":"M Papo","year":"2014","unstructured":"Papo M, Bielefeld P, Vallet H, Seve P, Wechsler B, Cacoub P, et al. Tocilizumab in severe and refractory non- infectious uveitis. Clin Exp Rheumatol. 2014;32 Suppl 84:S75\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"681_CR48","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3349\/ymj.2015.56.4.1158","volume":"56","author":"JY Park","year":"2015","unstructured":"Park JY, Chung YR, Lee K, Song JH, Lee ES. Clinical experience of interferon Alfa-2a treatment for refractory Uveitis in Beh\u00e7et's disease. Yonsei Med J. 2015;56(4):1158\u201362.","journal-title":"Yonsei Med J"},{"issue":"suppl 24","key":"681_CR49","first-page":"S6","volume":"19","author":"A Gul","year":"2001","unstructured":"Gul A. Beh\u00e7et\u2019s disease : an update on the pathogenesis. Clin Exp Rheumatol. 2001;19(suppl 24):S6\u201312.","journal-title":"Clin Exp Rheumatol"},{"key":"681_CR50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2249.1997.274-ce1159.x","volume":"107","author":"N Yamashita","year":"1997","unstructured":"Yamashita N, Kaneoka H, Kaneko S, et al. Role of gammadelta T lymphocytes in the development of Beh\u00e7et\u2019s disease. Clin Exp Immunol. 1997;107:241\u20137.","journal-title":"Clin Exp Immunol"},{"key":"681_CR51","first-page":"1544","volume":"20","author":"JL Mege","year":"1993","unstructured":"Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte-derive TNF-a, IL-6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544\u20139.","journal-title":"J Rheumatol"},{"key":"681_CR52","first-page":"128","volume":"24","author":"B Turan","year":"1997","unstructured":"Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Beh\u00e7et\u2019s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128\u201332.","journal-title":"J Rheumatol"},{"key":"681_CR53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-a, sIL-2R, OL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease. Mediat Inflamm. 2002;11:87\u201393.","journal-title":"Mediat Inflamm"},{"key":"681_CR54","unstructured":"Chronopoulou H, Tzavara V, Oikonomopoulos N, et al. High levels of TNF-a in the in the aqueous humor in patients suffering from Adamantiades-Beh\u00e7et\u2019s disease: preliminary results. Invest Ophthalmol Vis Sci. 2001;42(suppl 4)S708."},{"key":"681_CR55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","volume":"33","author":"M Santos Lacomba","year":"2001","unstructured":"Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251\u20135.","journal-title":"Ophthalmic Res"},{"key":"681_CR56","doi-asserted-by":"crossref","unstructured":"Sukumaran S, Marzan K, Shaham B, Reiff A. High dose Infliximab in the Treatment of Refractory Uveitis: Does Dose Matter? ISRN Rheumatol. 2012;2012:765380.","DOI":"10.5402\/2012\/765380"},{"issue":"7","key":"681_CR57","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362\u20138.","journal-title":"J Rheumatol"},{"issue":"7","key":"681_CR58","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of Infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903\u201312.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"681_CR59","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease. Ann Intern Med. 2004;140(5):404\u20136.","journal-title":"Ann Intern Med"},{"issue":"3","key":"681_CR60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","volume":"50","author":"N Markomichelakis","year":"2011","unstructured":"Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single Infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2019s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"681_CR61","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","volume":"146","author":"KF Tabbara","year":"2008","unstructured":"Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease. Am J Ophthalmol. 2008;146(6):845\u201350.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"681_CR62","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","volume":"36","author":"MM Hamza","year":"2016","unstructured":"Hamza MM, Macky TA, Sidky MK, Ragab G, Soliman MM. Intravitreal Infliximab in refractory Uveitis in Beh\u00e7et\u2019s disease: a safety and efficacy clinical study. Retina. 2016;36(12):2399\u2013408.","journal-title":"Retina"},{"issue":"12","key":"681_CR63","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, K\u00f6tter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, St\u00fcbiger N, Yurdakul S. Yazici H; EULAR expert committee. EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis. 2008;67(12):1656\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"681_CR64","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","volume":"68","author":"H Vallet","year":"2016","unstructured":"Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. Infliximab versus Adalimumab in the treatment of refractory inflammatory Uveitis: a multicenter study from the French Uveitis network. Arthritis Rheumatol. 2016;68(6):1522\u201330.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 5","key":"681_CR65","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","volume":"51","author":"A Rubbert-Roth","year":"2012","unstructured":"Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012;51(Suppl 5):v38\u201347.","journal-title":"Rheumatology"},{"key":"681_CR66","first-page":"S54","volume":"29","author":"I Olivieri","year":"2011","unstructured":"Olivieri I, Leccese P, D'Angelo S, Padula A, Nigro A, Palazzi C, et al. Efficacy of Adalimumab in patients with Beh\u00e7et's disease unsuccessfully treated with Infliximab. Clin Exp Rheumatol. 2011;29:S54.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"681_CR67","first-page":"824","volume":"21","author":"B Mushtaq","year":"2007","unstructured":"Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Beh\u00e7et\u2019s disease. Eye [Lond]. 2007;21(6):824\u20135.","journal-title":"Eye [Lond]"},{"issue":"3","key":"681_CR68","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","volume":"18","author":"A Bawazeer","year":"2010","unstructured":"Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with Adalimumab in the treatment of ocular Beh\u00e7et disease. Ocul Immunol Inflamm. 2010;18(3):226\u201332.","journal-title":"Ocul Immunol Inflamm"},{"key":"681_CR69","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s10067-008-0857-5","volume":"27","author":"V Curigliano","year":"2008","unstructured":"Curigliano V, Giovinale M, Fonnesu C, Cerquaglia C, Verrecchia E, Turco S, et al. Efficacy of Etanercept in the treatment of a patient with Beh\u00e7et\u2019s disease. Clin Rheumatol. 2008;27:933\u20136.","journal-title":"Clin Rheumatol"},{"key":"681_CR70","doi-asserted-by":"crossref","first-page":"ii51","DOI":"10.1136\/ard.61.suppl_2.ii51","volume":"61 Suppl 2","author":"P Sfikakis","year":"2002","unstructured":"Sfikakis P. Beh\u00e7et\u2019s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61 Suppl 2:ii51\u20133.","journal-title":"Ann Rheum Dis"},{"key":"681_CR71","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","volume":"45","author":"RK Saurenmann","year":"2006","unstructured":"Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor {alpha} inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45:982\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"681_CR72","first-page":"ii51","volume":"61 Suppl 2","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C, Giampetro C, Gaujoux T, Ea HK, Prati C, Orcel P, Wendling D, Liot\u00e9 F. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;61 Suppl 2:ii51\u20133.","journal-title":"J Rheumatol"},{"issue":"3","key":"681_CR73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumour necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785\u201396.","journal-title":"Ophthalmology"},{"issue":"2","key":"681_CR74","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","volume":"21","author":"M Mesquida","year":"2013","unstructured":"Mesquida M, Victoria Hern\u00e1ndez M, Lloren\u00e7 V, Pelegr\u00edn L, Espinosa G, Dick AD, et al. Beh\u00e7et disease associated uveitis successfully treated with Golimumab. Ocul Immunol Inflamm. 2013;21(2):160\u20132.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6 Suppl 102","key":"681_CR75","first-page":"S34","volume":"34","author":"M Santos-G\u00f3mez","year":"2016","unstructured":"Santos-G\u00f3mez M, Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, Mesquida M, Ad\u00e1n A. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet\u2019s disease: results of a multicenter open label study. Clin Exp Rheumatol. 2016;34(6 Suppl 102):S34\u201340.","journal-title":"Clin Exp Rheumatol"},{"issue":"47","key":"681_CR76","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359\u201368.","journal-title":"Oncogene"},{"issue":"5","key":"681_CR77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1078\/0171-2985-00200","volume":"206","author":"C Kneitz","year":"2002","unstructured":"Kneitz C, Wilhelm M, Tony H. Effective B cell depletion with rituximab in treatment of autoimmune diseases. J Immunobiol. 2002;206(5):519\u201327.","journal-title":"J Immunobiol"},{"issue":"3","key":"681_CR78","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","volume":"18","author":"S Sadreddini","year":"2008","unstructured":"Sadreddini S, Noshad S, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet\u2019s disease with Rituximab. Mod Rheumatol. 2008;18(3):306\u20138.","journal-title":"Mod Rheumatol"},{"key":"681_CR79","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Beh\u00e7et\u2019s disease; randomized single-blind control study [pilot study]. Int J Rheum Dis. 2010;13:246\u201352.","journal-title":"Int J Rheum Dis"},{"key":"681_CR80","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","volume":"22","author":"T Hirano","year":"2012","unstructured":"Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, et al. A case of Beh\u00e7et\u2019s disease treated with a humanized anti- interleukin-6 receptor antibody. Tocilizumab Mod Rheumatol. 2012;22:298\u2013302.","journal-title":"Tocilizumab Mod Rheumatol"},{"issue":"6","key":"681_CR81","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","volume":"45","author":"A Deroux","year":"2016","unstructured":"Deroux A, Chiquet C, Bouillet L. Tocilizumab in severe and refractory Behcet\u2019s disease: four cases and literature review. Semin Arthritis Rheum. 2016;45(6):733\u20137.","journal-title":"Semin Arthritis Rheum"},{"key":"681_CR82","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Beh\u00e7et\u2019s disease: a case series. Clin Rheum 2015;34 : 1293-1301.","journal-title":"Clin Rheum"},{"issue":"12","key":"681_CR83","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/cr.2010.130","volume":"20","author":"H Yang","year":"2010","unstructured":"Yang H, Wang J, Du J, et al. Structural basis of immunosuppression by the therapeutic antibody daclizumab. Cell Res. 2010;20(12):1361\u201371.","journal-title":"Cell Res"},{"issue":"5","key":"681_CR84","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00417-009-1043-4","volume":"247","author":"P Bhat","year":"2009","unstructured":"Bhat P, Casta\u00f1eda-Cervantes RA, Doctor PP, Foster CS. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):687\u201392.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"681_CR85","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(02)01932-2","volume":"110","author":"GN Papaliodis","year":"2003","unstructured":"Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110(4):786\u20139.","journal-title":"Ophthalmology"},{"issue":"5","key":"681_CR86","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ajo.2009.06.003","volume":"148","author":"HN Sen","year":"2010","unstructured":"Sen HN, Levy-clarke G, Faia LJ, et al. High-dose Daclizumab for the treatment of juvenile idiopathic arthritis\u2013associated active anterior Uveitis. Am J Ophthalmol. 2010;148(5):696\u2013703.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"681_CR87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","volume":"15","author":"RR Buggage","year":"2007","unstructured":"Buggage RR, Levy-clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of Daclizumab to treat the ocular complications related to Beh\u00e7et\u2019s disease Ronald. Ocul Immunol Inflamm. 2007;15(2):63\u201370.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"681_CR88","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcjo.2011.06.008","volume":"46","author":"K Wroblewski","year":"2011","unstructured":"Wroblewski K, Sen HN, Yeh S, Faia L, Li Z, Sran P et al. Long-term daclizumab therapy for the treatment of non-infectious ocular inflammatory disease. Can J Opthalmol. 2011;46[4]:322\u201328.","journal-title":"Can J Opthalmol."},{"issue":"1","key":"681_CR89","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmb.2012.09.021","volume":"425","author":"M Blech","year":"2013","unstructured":"Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, et al. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1\u03b2. J Mol Biol. 2013;425(1):94\u2013111.","journal-title":"J Mol Biol"},{"issue":"9","key":"681_CR90","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Beh\u00e7et\u2019s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71(9):1589\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"681_CR91","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Lopalco G, Vanozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with Anakinra and Canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191\u20137.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"681_CR92","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1betaregulating antibody XOMA 052 [Gevokizumab] in the treatment of acute exacerbations of resistant uveitis of Beh\u00e7et\u2019s disease: an openlabel pilot study. Ann Rheum Dis. 2012;71(4):563\u20136.","journal-title":"Ann Rheum Dis"},{"key":"681_CR93","unstructured":"XOMA. XOMA Announces Results From Phase 3 EYEGUARD\u2122-B Study. XOMA 2015. Available from url: http:\/\/investors.xoma.com\/releasedetail.cfm?ReleaseID=923200 . Accessed 27 Feb 2016."},{"key":"681_CR94","doi-asserted-by":"crossref","unstructured":"Zhou Z, Chen S, Shen N, Lu Y. Cytokines and Beh\u00e7et\u2019s disease. Autoimmun Rev. 2012;11:699\u2013704.","DOI":"10.1016\/j.autrev.2011.12.005"},{"issue":"4","key":"681_CR95","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","volume":"21","author":"JK Kolls","year":"2004","unstructured":"Kolls JK, Lind\u00e9n A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467\u201376.","journal-title":"Immunity"},{"issue":"3","key":"681_CR96","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/cmi.2010.21","volume":"7","author":"S Xu","year":"2010","unstructured":"Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7(3):164\u201374.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"681_CR97","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777\u201387.","journal-title":"Ophthalmology"},{"key":"681_CR98","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I Kotter","year":"2004","unstructured":"Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum. 2004;33:320\u201335.","journal-title":"Semin Arthritis Rheum"},{"key":"681_CR99","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","volume":"33","author":"I Kotter","year":"2004","unstructured":"Kotter I, Vonthein R, Zierhut M, Eckstein A, Ness T, Gunaydin I, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Beh\u00e7et disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33:311\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"681_CR100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I Kotter","year":"2003","unstructured":"Kotter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423\u201331.","journal-title":"Br J Ophthalmol"},{"key":"681_CR101","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","volume":"129","author":"S Onal","year":"2011","unstructured":"Onal S, Kazokogl H, Koc A, Akman M, Bavbek T. Direskeneli Hm et al. long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis. Arch Ophthalmol. 2011;129:288\u201394.","journal-title":"Arch Ophthalmol"},{"key":"681_CR102","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","volume":"62","author":"M Calguneri","year":"2003","unstructured":"Calguneri M, Ozturk M, Ertenli I, Kiraz S, Apras S, Ozbalkan Z. Effects of interferon alpha treatment on the clinical course of refractory Beh\u00e7et\u2019s disease: an open study. Ann Rheum Dis. 2003;62:492\u20133.","journal-title":"Ann Rheum Dis"},{"key":"681_CR103","first-page":"928","volume":"4","author":"V Hamuryudan","year":"2003","unstructured":"Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Beh\u00e7et\u2019s disease: an open study. Isr Med Assoc J. 2003;4:928\u201330.","journal-title":"Isr Med Assoc J"},{"key":"681_CR104","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","volume":"8","author":"B Wechsler","year":"2002","unstructured":"Wechsler B, Bodaghi B, Huong D, Fardeau C, Amoura Z, Cassoux N, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm. 2002;8:293\u2013301.","journal-title":"Ocul Immunol Inflamm"},{"key":"681_CR105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/jop.2011.0238","volume":"28","author":"F Yalcindag","year":"2012","unstructured":"Yalcindag F, Uzun A. Results of interferon alpha-2a therapy in patients with Beh\u00e7et\u2019s disease. J Ocul Pharmacol Ther. 2012;28:439\u201343.","journal-title":"J Ocul Pharmacol Ther"},{"key":"681_CR106","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00347-003-0927-7","volume":"101","author":"C Deuter","year":"2004","unstructured":"Deuter C, Kotter I, Gunaydin I, Zierhut M, Stubiger N. Ocular involvement in Beh\u00e7et\u2019s disease: first 5-year-results for visual development after treatment with interferon alfa-2a. Ophthalmologe. 2004;101:129\u201334.","journal-title":"Ophthalmologe"},{"key":"681_CR107","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"C Deuter","year":"2010","unstructured":"Deuter C, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease. Arthritis Rheum. 2010;62:2796\u2013805.","journal-title":"Arthritis Rheum"},{"key":"681_CR108","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","volume":"91","author":"B Bodaghi","year":"2007","unstructured":"Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong Du L. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335\u20139.","journal-title":"Br J Ophthalmol"},{"key":"681_CR109","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/0-306-48382-3_103","volume":"528","author":"L Krause","year":"2003","unstructured":"Krause L, Turnbull J, Torun N, Pleyer U, Zouboulis C, Foerster M. Interferon alfa-2a in the treatment of ocular Adamantiades- Beh\u00e7et\u2019s disease. Adv Exp Med Biol. 2003;528:511\u20139.","journal-title":"Adv Exp Med Biol"},{"key":"681_CR110","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"I Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:1692\u20135.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"681_CR111","doi-asserted-by":"crossref","unstructured":"Bielefeld P, Devilliers H, Deschasse C, Saadoun D, S\u00e8ve P, Muselier A, et al. Potential of Pegylated interferon alpha-2a in Beh\u00e7et Uveitis: a report of five cases. Ocul Immunol Inflamm. 2015Aug;24:1-4.","DOI":"10.3109\/09273948.2015.1010652"},{"key":"681_CR112","doi-asserted-by":"crossref","unstructured":"Aydinoglu-Candan \u00d6, Araz-Er\u015fan B, Gul A, Badur S and Tugal-Tutkun I. Anti-interferon alpha antibodies and autoantibodies in patients with Beh\u00e7et's disease uveitis treated with recombinant human interferon alpha-2a. Graefes Arch Clin Exp Opthalmol. 2015Mar;253 [3]:457-65.","DOI":"10.1007\/s00417-014-2856-3"},{"key":"681_CR113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09273948.2016.1134221","volume":"24","author":"M Hasanreisoglu","year":"2016","unstructured":"Hasanreisoglu M, Cubuk MO, Ozdek S, Guralik G, Aktas Z, Hasanreisoglu B. Interferon alpha-2a therapy in patients with refractory Beh\u00e7et Uveitis. Ocul Immunol Inflamm. 2016;24:1\u20135.","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"681_CR114","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s10067-016-3318-6","volume":"35","author":"H Kavandi","year":"2016","unstructured":"Kavandi H, Khabbazi A, Kolahi S, Haiialilo M, Shavan FK, Oliaei M. Long-term efficacy and safety of interferon \u03b1-2a therapy in severe refractory ophthalmic Beh\u00e7et\u2019s disease. Clin Rheumatol. 2016;35(11):2765\u20139.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"681_CR115","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","volume":"74","author":"S Lightman","year":"2015","unstructured":"Lightman S, Taylor SR, Bunce C, Longhurst H, Lynn W, Stanford M, et al. Pegylated interferon \u03b1-2b reduces corticosteroid requirement in patients with Behcet\u2019s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74(6):1138\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 84","key":"681_CR116","first-page":"S175","volume":"32","author":"Y Keskin","year":"2014","unstructured":"Keskin Y, Seyahi E, Poyraz C, Ugurlu S, Ozyazgan Y, Yazici H. Interferon alfa-associated depression in patients with Beh\u00e7et\u2019s syndrome: a prospective controlled study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S175.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"681_CR117","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bjophthalmol-2012-302515","volume":"97","author":"T Sakai","year":"2013","unstructured":"Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, et al. Health- and vision-related quality of life in patients receiving Infliximab therapy for Beh\u00e7et uveitis. Br J Ophthalmol. 2013;97(3):338\u201342.","journal-title":"Br J Ophthalmol"},{"key":"681_CR118","doi-asserted-by":"crossref","unstructured":"Kelly CJ, Mr FA. Economics of biologic therapies. BMJ 2009;339:b3276. Available from url: http:\/\/www.bmj.com\/content\/339\/bmj.b3276 . Accessed 13 Jan 2017.","DOI":"10.1136\/bmj.b3276"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0681-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T11:15:47Z","timestamp":1569842147000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0681-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0681-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]},"article-number":"130"}}